Skip to main content
Category

News

IonQ Completes Acquisition of Capella Space, Advancing Vision for Space-Based Quantum Communications

By News

COLLEGE PARK, MD – July 15, 2025 – IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced the completion of its acquisition of Capella Space Corporation, an American space tech company with synthetic aperture radar (SAR) and satellite solutions for government and commercial applications.

The closing marks a significant step in IonQ’s mission to develop the world’s first space-to-space and space-to-ground satellite quantum key distribution (QKD) network, enabling quantum-secure global communications.

With the acquisition now finalized, IonQ will begin developing a space-based QKD network by integrating Capella’s satellite infrastructure with its quantum technology. Once complete, this QKD network will enable secure communications that prevents encryption keys from being intercepted or copied without detection. It will also serve as a platform for additional quantum networking and sensing growth vectors. Capella customers will have access to rapid, ultra-secure SAR and remote sensing through the first quantum-enabled Earth observation platform.

“We have an exceptional opportunity to accelerate our vision for the quantum internet, where global QKD will play a foundational role in enabling secure communications,” said Niccolo de Masi, CEO of IonQ. “The integration of Capella’s advanced space-based platform and proven constellation of deployed satellites – along with IonQ’s quantum technologies – is expected to bolster commercial applications, global defense, and intelligence missions.”

“Capella has been a long-time pioneer in space technology and we can now take actionable steps to push the boundaries further by building the first quantum-enabled Earth observation platform,” said Frank Backes, CEO of Capella. “We’re excited to be joining the IonQ team on this new journey.”

This acquisition, along with the previously announced ID Quantique agreement, strengthens IonQ’s position in advancing quantum networking technologies that are essential for building the quantum internet. This news builds on recent quantum networking contracts with the Applied Research Laboratory for Intelligence and Security (ARLIS) and the U.S. Air Force Research Laboratory (AFRL).

About IonQ
IonQ, Inc. (NYSE: IONQ) is a leading commercial quantum computing, quantum networking, and quantum applications company, delivering high-performance systems aimed at solving the world’s most complex problems. IonQ’s current generation quantum computers, IonQ Forte andIonQ Forte Enterprise, are the latest in a line of cutting-edge systems that have been helping customers and partners such as Amazon Web Services, AstraZeneca and NVIDIA achieve 20x performance results. The company is accelerating its technology roadmap and intends to deliver the world’s most powerful quantum computers with 2M qubits by 2030 to accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity and defense. IonQ’s advancements in quantum networking also positions the company as a leader in building the quantum internet.

The company’s innovative technology and rapid growth were recognized in Newsweek’s 2025 Excellence Index 1000, Forbes’ 2025 Most Successful Mid-Cap Companies list, and Built In’s 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com

IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “accelerate,” “achieve,” “advancing,” “building,” “enabling,” “expected,” “intends,” “mission,” “opportunity,” “pioneer,” “position,” “push,” “support,” “vision,” “will” and other similar expressions are intended to identify forward-looking statements. These statements include those related to IonQ’s acquisition of, and partnerships with, other quantum computing companies, IonQ’s ability to effectively consummate and integrate such acquisitions and partnerships and the expected benefits thereof. IonQ’s quantum computing capabilities and plans; IonQ’s technology driving commercial quantum advantage or delivering scalable, fault-tolerant quantum computing in the future; the relevance and utility of quantum algorithms and applications run on IonQ’s quantum computers; the success of partnerships and collaborations between IonQ and other parties, including development and commercialization of products and services with such parties; the necessity, effectiveness, and future impacts of IonQ’s offerings available today; and the scalability, fidelity, efficiency, viability, accessibility, effectiveness, importance, reliability, performance, speed, impact, practicality, feasibility, and commercial-readiness of IonQ’s offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ’s ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ’s ability to deliver, and customers’ ability to generate, value from IonQ’s offerings; IonQ’s ability to deliver higher speed and fidelity gates with fewer errors, enhance information transfer and network accuracy, or reduce noise and errors; IonQ’s ability to sell effectively to government entities and large enterprises; changes in laws and regulations affecting IonQ’s and its suppliers’ businesses; IonQ’s ability to implement its business plans, forecasts, roadmaps and other expectations, to identify and realize partnerships and opportunities, and to engage new and existing customers; IonQ’s ability to effectively enter new markets; IonQ’s ability to deliver services and products within currently anticipated timelines; IonQ’s inability to attract and retain key personnel; IonQ’s customers deciding or declining to extend contracts into new phases; the inability of IonQ’s suppliers to deliver components that meet expectations timely; changes in U.S. government spending or policy that may affect IonQ’s customers; and risks associated with U.S. government sales, including availability of funding and provisions that allow the government to unilaterally terminate or modify contracts for convenience; changes in laws and regulations affecting IonQ’s patents; and IonQ’s ability to maintain or obtain patent protection for its products and technology, including with sufficient breadth to provide a competitive advantage. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent periodic financial report (10-Q or 10-K) filed by IonQ with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.

Contacts

IonQ Media Contact:

press@ionq.com

IonQ Investor Contact:

investors@ionq.co

Genome Editor Banner250

UM School of Medicine Team Wins NIH TARGETED Challenge with Brain Genome Editing Technology

By News

Genome Editor Banner250July 14, 2025 | Jon Kelvey – A team of researchers from the University of Maryland School of Medicine (UMSOM) recently won a $250,000 prize from the National Institutes of Health (NIH) to improve technologies for delivering genome editing tools to targeted cells in the body. They were one of four winners in a competition after successfully demonstrating a new technique to deliver genome editing biotechnology across the blood-brain barrier to brain cells in preclinical models. 

Read More
Marylandglobal250

Now Enrolling: Maryland Global Consulting Program Relaunches This Fall

By News

Marylandglobal250Maryland companies looking to expand their global reach can now apply for the Maryland Global Consulting Program, returning this fall with a new cohort of student-led international business consulting teams. Projects begin the week of September 22, 2025, and enrollment is open on a rolling basis.

Organized in partnership with the University of Maryland’s Smith School of Business and the Maryland Department of Commerce, this program pairs local companies with graduate student teams to solve global business challenges and support international expansion efforts.

Read More
endpoint

Endpoint News: Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

By News

endpointBy John Carroll, Editor & Founder – The numbers aren’t all bad in biotech. But you’d be forgiven if you thought they were. And you’d be in good company. Once again, Chris Dokomajilar at DealForma has been checking the data for us on what Q2 and the first half indicate for the rest of 2025. Once again, Chris Dokomajilar at DealForma has been checking the data for us on what Q2 and the first half indicate for the rest of 2025.

Significantly, dealmaking is holding up, particularly for prime late-stage drugs, as M&A popped a bit in the first half of this year and licensing numbers edged up in biotech. But once you look past dealmaking, it’s a question of just how much the numbers have eroded from last year — or last quarter.

Read More
NSF

NSF advances 29 semifinalists in the second NSF Regional Innovation Engines competition

By News

NSFJuly 8, 2025 – The U.S. National Science Foundation Regional Innovation Engines (NSF Engines) program announced the 29 semifinalists advancing to the next stage of the second competition – spanning critical technologies and applications ranging from energy grid security to maximizing the yield of critical minerals mining to advanced optical sensors. The semifinalist teams, many of whom have been building their regional coalitions for a year or longer, are led by universities, nonprofits, private industry and other organizations from across the United States. View a map of the NSF Engines semifinalists.

Read More
Accelerate

Top Innovators Wanted! APPLY NOW! Accelerate Investor Conference

By News

AccelerateThe Accelerate Investor Conference is a venture investor and startup conference and early stage business competition that showcases our region as a powerhouse for innovation and business opportunity.

The competition fuels innovation-based business growth by showcasing the best and brightest new tech startups to potential investors to foster their development.

Dozens of top tech companies and 20+ student teams will compete to win cash and bragging rights. The competition targets entrepreneurs with early to mid seed stage, high growth businesses with the potential to have an immediate and positive impact on our local economy, as well as student concepts with longer-term business viability.

 

Read More
Cel Sci

CEL-SCI Announces $5.7M At-the-Market Offering

By News

Cel SciVIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock is being sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be approximately $5.7 million. The offering is expected to close on July 14, 2025, subject to satisfaction of customary closing conditions.

Read More
CelSci

CEL-SCI to Partner With Top Saudi Pharma on Cancer Treatment

By News

CelSciVIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (NYSE American: CVM) today announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical and healthcare companies for a partnership that spans regulatory and commercial activities for Multikine* (Leukocyte Interleukin, Injection) in the Kingdom of Saudia Arabia. The formal agreement is expected to be signed with the Saudi pharmaceutical partner which will file a Breakthrough Medicine Designation application for Multikine with the Saudi Food and Drug Authority (SFDA) in the coming weeks. According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days. Following the granting of the Breakthrough Medicine Designation, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia. Several leading Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market.

Read More
arpafunding

ARPA-H Launches Brain Recovery Program; Proposers’ Day Registration Now Open

By News

arpafundingToday, the Advanced Research Projects Agency for Health (ARPA-H) announced its groundbreaking Functional Repair of Neocortical Tissue (FRONT) program, a transformative initiative to restore brain function and position the U.S. as the global leader in brain repair technology. FRONT aims to use cutting-edge neurodevelopmental principles and stem cell technology to regenerate brain tissue and restore lost functions. 

Read More

Previous BHCR Crab Trap Winner Nanochon Announces Health Canada Approval for First Human Investigation

By News, News Archive

Washington, DC, July 10 2025 – Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was granted Health Canada Approval for their first in human clinical trial.NanoChon

The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with Sports Medicine Specialists, Drs. Joel Lobo, Kajeandra Ravichandiran and Marcin Kowalczuk as Sub-Investigators, at the Durham Bone & Joint Specialists (DBJS), located in Ontario, Canada. Dr. Fathi Abuzgaya, is an orthopedic surgeon by training and an esteemed researcher with a track record over the last 25 years, leading +600 clinical trials in all phases and therapeutic areas.

“Our team is delighted that we are the first center to start enrolling participants for the Chondrograft™ study, which represents a novel, minimally invasive treatment for patients with loss of or damaged knee cartilage,” Dr. Abuzgaya commented. “DBJS is a multidisciplinary musculoskeletal center providing non-operative and operative treatments with accessibility to a variety of sub-specialties. Our study site with dedicated researchers enables greater, more efficient patient recruitment for clinical research and we are privileged to support Nanochon.”

The Nanochon Chondrograft™ System is being evaluated in a prospective, 10 patient, early feasibility study for use in knee cartilage restoration in eligible patients between 22 and 60 years of age having femoral condyle and /or trochlea articular cartilage lesions who have failed conservative therapy, in addition to meeting other criteria. The study is designed to assess the safety and performance of Chondrograft™, and procedural goals include regrowth of the cartilage-bone matrix, improvement in knee function and pain, and delayed need for arthroplasty.

“Achieving Health Canada approval allows us to gain the clinical data needed to take a giant step forward towards design and execution of a large pivotal North American study” said Ben Holmes, CEO of Nanochon. “We have the utmost confidence in Dr. Abuzgaya and his clinical team at DBJS to help us recruit the right patients and execute the trial protocol that we have so carefully designed.”

While the first in human trial will take place in Canada, this represents just the first step towards a larger clinical program.

“Thousands of patients with chondral defects, that may evolve to osteoarthritis, live with a reduced quality of life. We are looking forward to the potential for a new treatment option and are excited to begin the Chondrograft™ study at DBJS”, states Dr. Joel Lobo.  “The results of this study could open up a new surgical option, that is minimally invasive to address this unmet clinical need.”

Throughout the clinical trial design and regulatory approval process, Nanochon was supported by HN Clinical Consulting (Missouri). “Improving the lives of young adults and athletes by providing a solution to restore knee cartilage and hopefully help patients avoid costly knee replacement is a crucial therapy needed in the orthopedic world,” said Heather Neill, Founder and Principal. “We appreciate Health Canada’s thought-provoking questions throughout their review that helped us put forward the strongest application possible, which ultimately led to our approval.” HN Clinical Consulting will continue to support the full life cycle of Chondrograft™.

About HN Clinical Consulting

HN Clinical Consulting, LLC, brings a strategic focus to each project, keeping the goal of commercialization in sight. Building strong relationships with all stakeholders and maintaining a clinical strategic goal of project-oriented success to support long term Sponsor strategy/exit is key to development of clinical programs.  The objective set is to stay ahead by planning for podium presence, publication, and reimbursement while designing the Clinical Investigational Plan.

About Nanochon

Nanochon is a biotech and medical device company focused on developing innovative orthopedic solutions. Chondrograft™ is a minimally-invasive implant that allows for immediate weight-bearing and motion – meaning less time spent recovering. The implant is based on research from the Tissue Engineering and Nanotechnology lab at the George Washington University, and is designed to integrate with healthy tissue over time, for maximum stability and benefit to the patient. Nanochon has the potential to deliver more successful and longer-lasting recovery for patients than current standard of care. Our mission is to develop a new approach to treat cartilage treatment so that the hundreds of thousands of young, active patients with joint damage can return to their lifestyles without undergoing costly and invasive short-term fixes.

www.nanochon.com

Contact

Rachel Offenburg, Chief of Strategy

rachel.offenburg@nanochon.com

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.